Illumina (ILMN)
(Delayed Data from NSDQ)
$117.61 USD
+3.12 (2.73%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $117.69 +0.08 (0.07%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth D Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ILMN 117.61 +3.12(2.73%)
Will ILMN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ILMN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ILMN
Why Illumina (ILMN) Could Beat Earnings Estimates Again
Wall Street Analysts Think Illumina (ILMN) Could Surge 27.02%: Read This Before Placing a Bet
ILMN: What are Zacks experts saying now?
Zacks Private Portfolio Services
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Illumina (ILMN) Upgraded to Buy: Here's Why
Other News for ILMN
3 Precision Medicine Stocks Tailoring Treatments
Illumina to Present Upcoming Strategy Update
Patient Capital Management Q2 2024 Investment Review
Patient Capital Management Q2 2024 Commentary
Illumina Ventures Adds Two New Experts as Advisors